Life sciences organisation Cytiva has acquired a new facility in Michigan US to help it expand its resins manufacturing operations outside of Sweden.
The company’s new chromatography resins manufacturing site will be based in Muskegon, Michigan and forms part of Cytiva and Pall Corporation’s $1.5 billion capacity expansion investment.
Cytiva plans to transform the site into a 168,000 square-foot biomanufacturing centre. Cytiva will expand beyond Sweden to manufacture these resins, media that is critical in purifying and analysing biomolecules so pharmaceutical and life sciences companies can make medicines. The facility will be home to approximately 200 associates when completed.
The site is being supported by the Michigan Economic Development Corporation (MEDC), the Michigan Strategic Fund (MSF), and a co-operative agreement funded through the Biomedical Advanced Research and Development Authority (BARDA).
Cytiva is planning to start construction on the site in Q3 of 2022 with manufacturing expected to begin in 2026.
Emmanuel Ligner, Danaher Group Executive and President and CEO of Cytiva, said: “This shows our leadership in action, strengthening our focus on providing customers who use our resins to manufacture vaccines and life-saving therapeutics.”
“When you’re looking to help provide global biotechnology solutions to the world, it requires you to be nimble and flexible. By investing in Muskegon, Michigan, we will be closer to our North American customers, who are developing advanced biotherapeutics.”
Governor Gretchen Whitmer of Michigan, added: “Cytiva’s investment in Muskegon will create good-paying jobs and build on West Michigan’s strength as a life sciences hub. I am thrilled that Cytiva is investing in Muskegon, and I look forward to further collaboration as we continue growing Michigan’s economy.”